/images/ppid_59c68470-image-176822256675945177.webp)
![[WATCH] BBL 2025-26: Mohammad Rizwan retired out after sluggish knock against Sydney Thunder](https://glance-mob.glance-cdn.com/public/cardpress/binge-magazine-card-generation/spaces/IN/en/crictracker-spaces/images/ppid_49c02804-image-176822014773876936.webp)
What is the story about?
Biocon Limited’s board has approved a Qualified Institutional Placement (QIP), setting the floor price for the issue at ₹387.74 per equity share. The approval was granted at a board meeting held on 6 December 2025, following a special resolution passed by shareholders at an Extra-ordinary General Meeting on 31 December 2025.
The Fund Raising Committee authorised the opening of the issue on 12 January 2026 and approved the preliminary placement document, along with the application form for the QIP. The committee also fixed the ‘relevant date’ for the purpose of the issue as 12 January 2026. In line with SEBI ICDR Regulations, the company may offer a discount of up to 5% on the floor price at its discretion. The final issue price will be determined in consultation with the book running lead managers appointed for the placement.
The QIP is sized at ₹4,150 crore, with an indicative issue price of ₹368.35, representing the maximum 5% discount on the floor price. The SEBI floor is set at ₹387.74, and the stock closed at ₹371.8, reflecting investor sentiment ahead of the placement.
On 7 January 2026, Biocon’s subsidiary announced plans to launch three new oncology biosimilars in the future at a US healthcare conference, reinforcing its commitment to affordable cancer care and expanding its global presence.
Also read: Biocon arm to introduce in future three new oncology biosimilars at US healthcare conference
Earlier, on 23 December 2025, Ajanta Pharma signed an in-licensing agreement with Biocon for marketing semaglutide across 26 countries. Semaglutide is indicated to improve glycaemic control in adults and is the active ingredient in brands such as Ozempic, marking a significant collaboration in diabetes care.
Also read: Ajanta Pharma signs in-licensing pact with Biocon for marketing semaglutide in 26 countries
Separately, a report noted that the credit-deposit ratio of banks has risen to 82%, reflecting increased lending relative to deposits and highlighting broader trends in banking activity.
Biocon Limited shares closed lower on the NSE at ₹370.90 on 12 January 2026, down ₹8.70 or 2.29% for the day, reflecting investor caution ahead of the QIP opening.
The Fund Raising Committee authorised the opening of the issue on 12 January 2026 and approved the preliminary placement document, along with the application form for the QIP. The committee also fixed the ‘relevant date’ for the purpose of the issue as 12 January 2026. In line with SEBI ICDR Regulations, the company may offer a discount of up to 5% on the floor price at its discretion. The final issue price will be determined in consultation with the book running lead managers appointed for the placement.
The QIP is sized at ₹4,150 crore, with an indicative issue price of ₹368.35, representing the maximum 5% discount on the floor price. The SEBI floor is set at ₹387.74, and the stock closed at ₹371.8, reflecting investor sentiment ahead of the placement.
On 7 January 2026, Biocon’s subsidiary announced plans to launch three new oncology biosimilars in the future at a US healthcare conference, reinforcing its commitment to affordable cancer care and expanding its global presence.
Also read: Biocon arm to introduce in future three new oncology biosimilars at US healthcare conference
Earlier, on 23 December 2025, Ajanta Pharma signed an in-licensing agreement with Biocon for marketing semaglutide across 26 countries. Semaglutide is indicated to improve glycaemic control in adults and is the active ingredient in brands such as Ozempic, marking a significant collaboration in diabetes care.
Also read: Ajanta Pharma signs in-licensing pact with Biocon for marketing semaglutide in 26 countries
Separately, a report noted that the credit-deposit ratio of banks has risen to 82%, reflecting increased lending relative to deposits and highlighting broader trends in banking activity.
Biocon Limited shares closed lower on the NSE at ₹370.90 on 12 January 2026, down ₹8.70 or 2.29% for the day, reflecting investor caution ahead of the QIP opening.
/images/ppid_a911dc6a-image-176822106534057540.webp)
/images/ppid_a911dc6a-image-176822103266774307.webp)
/images/ppid_a911dc6a-image-176822105853013318.webp)
